MGMT and glioblastoma: Since the most recent WHO classification from 2021, IDH-1 status gained relative importance over MGMT, and cases previously considered to be glioblastoma are now categorized as either glioblastoma (IDH-1 wild type) or astrocytoma grade 4 (IDH-1 mutated), two groups with very different survival rates.